Calon Cardio-Technology Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Calon Cardio-Technology Ltd
Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
Medtech start-ups are pioneering innovative device solutions for heart failure that they hope will end the vicious cycle of costly hospitalizations and declining patient health. Profiles of Calon-Cardio Technology, Cibiem, and DC Devices.
This Month's Profile Group: Medtech Start-Ups Aim To Reverse The Downward Spiral of Heart Failure, features profiles of BioVentrix, Calon Cardio-Technology, Cibiem, DC Devices, and LoneStar Heart. Plus these Start-Ups Across Health Care: Dialog Devices, Lumena Pharmaceuticals, and STAT-Diagnostica.
Ventricular assist devices are a viable long-term treatment option for patients with advanced heart failure, but their exorbitant price tag and their propensity to damage blood has limited their use. Calon Cardio-Technology Ltd. hopes to avoid those problems with its MiniVAD, which is similar in size and weight to the smallest existing VADs, but is designed to be more efficient and process blood flow more gently.
- Medical Devices
- Implantable Devices